<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318861</url>
  </required_header>
  <id_info>
    <org_study_id>KITE-585-501</org_study_id>
    <nct_id>NCT03318861</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kite, A Gilead Company</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of KITE-585, an autologous engineered CAR T-cell
      product targeting a protein commonly found on myeloma cells called BCMA. Patients will be
      given a 3 day course of chemotherapy followed by a single infusion of KITE-585.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with relapsed/refractory multiple myeloma can participate if all eligibility
      criteria are met. Tests required to determine eligibility include disease assessments, a
      physical exam, ECG and echocardiogram of the heart, brain MRI, and blood draws. Eligible
      participants have white blood cells collected by apheresis. These cells are genetically
      modified to make the experimental treatment KITE-585. Participants receive chemotherapy prior
      to the KITE-585 infusion. After the KITE-585 infusion, participants will be followed for side
      effects and effect of KITE-585 on their myeloma. Study procedures may be performed while
      hospitalized and/or in the outpatient setting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2017</start_date>
  <completion_date type="Anticipated">October 2032</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Arm, Dose-Escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events defined as DLTs</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Determine maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Objective response rate (partial response [PR] + very good PR (VGPR) + complete response [CR] + stringent CR [sCR]) according to International Myeloma Working Group (IMWG) Uniform Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>DOR is defined as the time from the first objective response to disease progression per IMWG Consensus Panel 1 Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>PFS defined as the time from KITE-585 infusion to the date of disease progression per the IMWG Consensus Panel 1 Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AE)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>The frequency of any AEs that occurred during study participation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in lab values</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>The occurrence of any changes in lab values deemed to be clinically significant during study participation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Relapsed/Refractory Muliple Myeloma Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 dose-escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Autologous genetically modified anti-BCMA CAR transduced T cells (KITE-585)</intervention_name>
    <description>A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells (KITE-585)</description>
    <arm_group_label>Relapsed/Refractory Muliple Myeloma Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Measurable relapsed or refractory myeloma as defined by the International Myeloma
             Working Group (IMWG) Consensus Criteria following treatment with at least 3 lines of
             therapy including with both a proteasome inhibitor (PI) and an immunomodulatory drug
             (IMiD), or progressive myeloma that is refractory to a regimen containing both a PI
             and an IMiD.

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          3. Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:

               -  Absolute neutrophil count (ANC) ≥ 1,000/µL

               -  Platelet count ≥ 75,000/µL

               -  Absolute lymphocyte count ≥ 100/µL

               -  Creatinine clearance above limits set in the protocol for each cohort

               -  Normal cardiac function as assessed by electrocardiogram (ECG) and echocardiogram

               -  Baseline oxygen saturation &gt; 92% on room air and no clinically significant
                  pleural effusion

        Key Exclusion Criteria:

          1. Plasma cell leukemia

          2. Non-secretory multiple myeloma

          3. History of CNS involvement by MM

          4. Prior CAR therapy or other genetically modified T cells

          5. Inadequate washout from prior therapy

          6. Autologous stem cell transplant within 6 weeks before enrollment or any history of
             allogenic transplant

          7. History of active autoimmune disease

          8. History of deep vein thrombosis or pulmonary embolism requiring systemic
             anticoagulation within 6 months before enrollment

          9. Recent history of other (non multiple myeloma) cancer

         10. Active viral, fungal, bacterial or other infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Koh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>844-454-KITE</phone>
    <email>medinfo@kitepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruck Habtemariam</last_name>
      <email>bhabtemariam@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Courtney</last_name>
      <email>clcourtney@mednet.ucla.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Scott</last_name>
      <email>matthew.scott@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Malloy</last_name>
      <email>rmalloy@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Linda Schroeder</last_name>
      <email>lschroed@medicine.bsd.uchicago.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noopur Raje, MD</last_name>
      <phone>617-724-4000</phone>
      <email>NRAJE@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracee Shevlin</last_name>
      <email>shevlin.tracee@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Hoover</last_name>
      <email>hoovere@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Rivas</last_name>
      <email>rivass@mskcc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Trials Information Program</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <contact_backup>
      <last_name>CAR-T Cell Line</last_name>
      <phone>615-936-2102</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Morphey</last_name>
      <email>alandry1@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Kent</last_name>
      <email>sskent@mdanderson.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

